Publications searcher

The science produced by our scientists is very important. In 2022, 1,629 papers were published in scientific journals with a global impact factor of over 15,000 points.

Quality assurance in specialized headache units in Spain: an observational prospective study.

PMID: 31238877
Journal: JOURNAL OF HEADACHE AND PAIN
Year: 2019
Reference: J Headache Pain. 2019 Jun 25;20(1):73. doi: 10.1186/s10194-019-1020-1.
Impact factor:
Publication type: Paper in international publication
Authors: Balseiro-Gomez, Jose; Guerrero-Peral, Angel L; Ignacio, Emilio; Latorre-Gonzalez, German; Layos-Romero, Almudena; Lucas, Cesar; Martinez-Garcia, Alba; Mira, Jose J; Pascual, Julio; Porta-Etessam, Jesus et al.
DOI: 10.1186/s10194-019-1020-1

Quantification of urinary derivatives of Phenylbutyric and Benzoic acids by LC-MS/MS as treatment compliance biomarkers in Urea Cycle disorders.

PMID: 31394303
Journal: JOURNAL OF PHARMACEUTICAL AND BIOMEDICAL ANALYSIS
Year: 2019
Reference: J Pharm Biomed Anal. 2019 Nov 30;176:112798. doi: 10.1016/j.jpba.2019.112798. Epub 2019 Aug 1.
Impact factor: 2.983
Publication type: Paper in international publication
Authors: Ruiz-Pons, Monica, Canedo, Elvira, Barba Romero, Miguel Angel, Garcia-Jimenez, M feminine Concepcion, Aldamiz-Echevarria, Luis, Del Toro, Mireia, Gil, David, Blasco, Javier, Andrade, Fernando, Vitoria, Isidro et al.
DOI: 10.1016/j.jpba.2019.112798

Quantification of urinary derivatives of Phenylbutyric and Benzoic acids by LC-MS/MS as treatment compliance biomarkers in Urea Cycle disorders.

PMID: 31394303
Journal: JOURNAL OF PHARMACEUTICAL AND BIOMEDICAL ANALYSIS
Year: 2019
Reference: J Pharm Biomed Anal. 2019 Nov 30;176:112798. doi: 10.1016/j.jpba.2019.112798. Epub 2019 Aug 1.
Impact factor:
Publication type: Paper in international publication
Authors: Aldamiz-Echevarria, Luis; Almeida Campos, Teresa; Andrade, Fernando; Barba Romero, Miguel Angel; Blasco, Javier; Canedo, Elvira; Ceberio, Leticia; Correcher, Patricia; de Las Heras, Javier; Del Toro, Mireia et al.
DOI: 10.1016/j.jpba.2019.112798

Radiation Exposure from Fluoroscopy during Hip Arthroscopy.

PMID: 31763460
Journal: Surgery journal (New York, N.Y.)
Year: 2019
Reference: Surg J (N Y). 2019 Nov 21;5(4):e184-e187. doi: 10.1055/s-0039-3400278. eCollection 2019 Oct.
Impact factor: 0
Publication type: Paper in international publication
Authors: Seijas, Roberto, Catala, Jordi, Cepas, Miguel Angel, Sallent, Andrea, Ares, Oscar, Barastegui, David et al.
DOI: 10.1055/s-0039-3400278

Radiation Exposure from Fluoroscopy during Hip Arthroscopy.

PMID: 31763460
Journal: Surgery journal (New York, N.Y.)
Year: 2019
Reference: Surg J (N Y). 2019 Nov 21;5(4):e184-e187. doi: 10.1055/s-0039-3400278. eCollection 2019 Oct.
Impact factor:
Publication type: Paper in international publication
Authors: Ares, Oscar; Barastegui, David; Catala, Jordi; Cepas, Miguel Angel; Sallent, Andrea; Seijas, Roberto et al.
DOI: 10.1055/s-0039-3400278

Radical Hysterectomy: Efficacy and Safety in the Dawn of Minimally Invasive Techniques.

PMID: 29908339
Journal: Journal of Minimally Invasive Gynecology
Year: 2019
Reference: J Minim Invasive Gynecol. 2019 Mar - Apr;26(3):492-500. doi: 10.1016/j.jmig.2018.06.007. Epub 2018 Jun 13.
Impact factor: 2.414
Publication type: Paper in international publication
Authors: Gil-Moreno, Antonio, Carbonell-Socias, Melchor, Salicru, Sabina, Centeno-Mediavilla, Cristina, Franco-Camps, Silvia, Colas, Eva, Oaknin, Ana, Perez-Benavente, Assumpcio, Diaz-Feijoo, Berta et al.
DOI: 10.1016/j.jmig.2018.06.007

Radical Hysterectomy: Efficacy and Safety in the Dawn of Minimally Invasive Techniques.

PMID: 29908339
Journal: Journal of Minimally Invasive Gynecology
Year: 2019
Reference: J Minim Invasive Gynecol. 2019 Mar - Apr;26(3):492-500. doi: 10.1016/j.jmig.2018.06.007. Epub 2018 Jun 13.
Impact factor:
Publication type: Paper in international publication
Authors: Carbonell-Socias, Melchor; Centeno-Mediavilla, Cristina; Colas, Eva; Diaz-Feijoo, Berta; Franco-Camps, Silvia; Gil-Moreno, Antonio; Oaknin, Ana; Perez-Benavente, Assumpcio; Salicru, Sabina et al.
DOI: 10.1016/j.jmig.2018.06.007

Radiotherapy practice for paediatric brain tumours across Europe and quality assurance initiatives: Current situation, international survey and future perspectives.

PMID: 31035085
Journal: EUROPEAN JOURNAL OF CANCER
Year: 2019
Reference: Eur J Cancer. 2019 Jun;114:36-46. doi: 10.1016/j.ejca.2019.03.018. Epub 2019 Apr 28.
Impact factor: 6.68
Publication type: Paper in international publication
Authors: de Rojas, Teresa, Clementel, Enrico, Giralt, Jordi, Cruz, Ofelia, Boterberg, Tom, Kortmann, Rolf-Dieter, Gaze, Mark N, Moreno, Lucas, Janssens, Geert O et al.
DOI: 10.1016/j.ejca.2019.03.018

Radiotherapy practice for paediatric brain tumours across Europe and quality assurance initiatives: Current situation, international survey and future perspectives.

PMID: 31035085
Journal: EUROPEAN JOURNAL OF CANCER
Year: 2019
Reference: Eur J Cancer. 2019 Jun;114:36-46. doi: 10.1016/j.ejca.2019.03.018. Epub 2019 Apr 28.
Impact factor:
Publication type: Paper in international publication
Authors: Boterberg, Tom; Clementel, Enrico; Cruz, Ofelia; de Rojas, Teresa; Gaze, Mark N; Giralt, Jordi; Janssens, Geert O; Kortmann, Rolf-Dieter; Moreno, Lucas et al.
DOI: 10.1016/j.ejca.2019.03.018

Radium-223 in asymptomatic patients with castration-resistant prostate cancer and bone metastases treated in an international early access program.

PMID: 30612558
Journal: BMC CANCER
Year: 2019
Reference: BMC Cancer. 2019 Jan 7;19(1):12. doi: 10.1186/s12885-018-5203-y.
Impact factor: 2.933
Publication type: Paper in international publication
Authors: Heidenreich, Axel, Gillessen, Silke, Heinrich, Daniel, Keizman, Daniel, O'Sullivan, Joe M, Carles, Joan, Wirth, Manfred, Miller, Kurt, Reeves, John, Seger, Monica et al.
DOI: 10.1186/s12885-018-5203-y

Radium-223 in asymptomatic patients with castration-resistant prostate cancer and bone metastases treated in an international early access program.

PMID: 30612558
Journal: BMC CANCER
Year: 2019
Reference: BMC Cancer. 2019 Jan 7;19(1):12. doi: 10.1186/s12885-018-5203-y.
Impact factor:
Publication type: Paper in international publication
Authors: Carles, Joan; Gillessen, Silke; Heidenreich, Axel; Heinrich, Daniel; Keizman, Daniel; Miller, Kurt; Nilsson, Sten; O'Sullivan, Joe M; Reeves, John; Saad, Fred et al.
DOI: 10.1186/s12885-018-5203-y

Ramucirumab plus pembrolizumab in patients with previously treated advanced non-small-cell lung cancer, gastro-oesophageal cancer, or urothelial carcinomas (JVDF): a multicohort, non-randomised, open-label, phase 1a/b trial.

PMID: 31301962
Journal: LANCET ONCOLOGY
Year: 2019
Reference: Lancet Oncol. 2019 Aug;20(8):1109-1123. doi: 10.1016/S1470-2045(19)30458-9. Epub 2019 Jul 10.
Impact factor: 35.386
Publication type: Paper in international publication
Authors: Arkenau, Hendrik-Tobias, Santana-Davila, Rafael, Calvo, Emiliano, Paz-Ares, Luis, Cassier, Philippe A, Bendell, Johanna, Penel, Nicolas, Krebs, Matthew G, Martin-Liberal, Juan, Isambert, Nicolas et al.
DOI: 10.1016/S1470-2045(19)30458-9

Ramucirumab plus pembrolizumab in patients with previously treated advanced non-small-cell lung cancer, gastro-oesophageal cancer, or urothelial carcinomas (JVDF): a multicohort, non-randomised, open-label, phase 1a/b trial.

PMID: 31301962
Journal: LANCET ONCOLOGY
Year: 2019
Reference: Lancet Oncol. 2019 Aug;20(8):1109-1123. doi: 10.1016/S1470-2045(19)30458-9. Epub 2019 Jul 10.
Impact factor:
Publication type: Paper in international publication
Authors: Arkenau, Hendrik-Tobias; Bendell, Johanna; Calvo, Emiliano; Cassier, Philippe A; Chau, Ian; Cultrera, Jennifer; Ferry, David; Fuchs, Charles S; Gao, Ling; Herbst, Roy S et al.
DOI: 10.1016/S1470-2045(19)30458-9

Ramucirumab with cisplatin and fluoropyrimidine as first-line therapy in patients with metastatic gastric or junctional adenocarcinoma (RAINFALL): a double-blind, randomised, placebo-controlled, phase 3 trial.

PMID: 30718072
Journal: LANCET ONCOLOGY
Year: 2019
Reference: Lancet Oncol. 2019 Mar;20(3):420-435. doi: 10.1016/S1470-2045(18)30791-5. Epub 2019 Feb 1.
Impact factor: 35.386
Publication type: Paper in international publication
Authors: Prausova, Jana, Van Cutsem, Eric, Ilson, David H, Alsina, Maria, Chau, Ian, Lacy, Jill, Ducreux, Michel, Mendez, Guillermo Ariel, Alavez, Alejandro Molina, Takahari, Daisuke et al.
DOI: 10.1016/S1470-2045(18)30791-5

Ramucirumab with cisplatin and fluoropyrimidine as first-line therapy in patients with metastatic gastric or junctional adenocarcinoma (RAINFALL): a double-blind, randomised, placebo-controlled, phase 3 trial.

PMID: 30718072
Journal: LANCET ONCOLOGY
Year: 2019
Reference: Lancet Oncol. 2019 Mar;20(3):420-435. doi: 10.1016/S1470-2045(18)30791-5. Epub 2019 Feb 1.
Impact factor:
Publication type: Paper in international publication
Authors: Acs, Peter Istvan; Al-Batran, Salah-Eddin; Alavez, Alejandro Molina; Alcindor, Thierry; Alsina, Maria; Aprile, Giuseppe; Asmis, Timothy R; Ayala, Hubert; Bajaj, Madhuri; Barone, Carlo et al.
DOI: 10.1016/S1470-2045(18)30791-5

Randomised phase 2 study of pembrolizumab plus CC-486 versus pembrolizumab plus placebo in patients with previously treated advanced non-small cell lung cancer.

PMID: 30654297
Journal: EUROPEAN JOURNAL OF CANCER
Year: 2019
Reference: Eur J Cancer. 2019 Feb;108:120-128. doi: 10.1016/j.ejca.2018.11.028. Epub 2019 Jan 14.
Impact factor: 6.68
Publication type: Paper in international publication
Authors: Paz-Ares, Luis, Levy, Benjamin P, Giaccone, Giuseppe, Besse, Benjamin, Felip, Enriqueta, Garassino, Marina Chiara, Domine Gomez, Manuel, Garrido, Pilar, Piperdi, Bilal, Ponce-Aix, Santiago et al.
DOI: 10.1016/j.ejca.2018.11.028

Randomised phase 2 study of pembrolizumab plus CC-486 versus pembrolizumab plus placebo in patients with previously treated advanced non-small cell lung cancer.

PMID: 30654297
Journal: EUROPEAN JOURNAL OF CANCER
Year: 2019
Reference: Eur J Cancer. 2019 Feb;108:120-128. doi: 10.1016/j.ejca.2018.11.028. Epub 2019 Jan 14.
Impact factor:
Publication type: Paper in international publication
Authors: Besse, Benjamin; Domine Gomez, Manuel; Fandi, Abderrahim; Felip, Enriqueta; Garassino, Marina Chiara; Garrido, Pilar; Giaccone, Giuseppe; Levy, Benjamin P; MacBeth, Kyle J; Menezes, Daniel et al.
DOI: 10.1016/j.ejca.2018.11.028

Randomized, Double-blind, Placebo-controlled, Multicenter Study of Siltuximab in High-risk Smoldering Multiple Myeloma.

PMID: 30890552
Journal: CLINICAL CANCER RESEARCH
Year: 2019
Reference: Clin Cancer Res. 2019 Jul 1;25(13):3772-3775. doi: 10.1158/1078-0432.CCR-18-3470. Epub 2019 Mar 19.
Impact factor: 8.911
Publication type: Paper in international publication
Authors: Goldschmidt, Hartmut, Brighton, Timothy A, Khot, Amit, Harrison, Simon J, Ghez, David, Weiss, Brendan M, Kirsch, Andreas, Magen, Hila, Gironella, Mercedes, Oriol, Albert et al.
DOI: 10.1158/1078-0432.CCR-18-3470

Randomized, Double-blind, Placebo-controlled, Multicenter Study of Siltuximab in High-risk Smoldering Multiple Myeloma.

PMID: 30890552
Journal: CLINICAL CANCER RESEARCH
Year: 2019
Reference: Clin Cancer Res. 2019 Jul 1;25(13):3772-3775. doi: 10.1158/1078-0432.CCR-18-3470. Epub 2019 Mar 19.
Impact factor:
Publication type: Paper in international publication
Authors: Bandekhar, Rajesh; Brighton, Timothy A; Ghez, David; Gironella, Mercedes; Goldschmidt, Hartmut; Guilfoyle, Mary; Harrison, Simon J; Hu, Peter; Khot, Amit; Kirsch, Andreas et al.
DOI: 10.1158/1078-0432.CCR-18-3470

Randomized phase II clinical trial to evaluate the efficacy of second-line FOLFIRI-panitumumab in patients with RAS wild-type metastatic colorectal cancer who have received FOLFOX-panitumumab in first-line (BEYOND).

PMID: 32085197
Journal: ANNALS OF ONCOLOGY
Year: 2019
Reference: Ann Oncol. 2019 Jul;30 Suppl 4:iv52. doi: 10.1093/annonc/mdz155.190. Epub 2019 Dec 4.
Impact factor: 14.196
Publication type: Letter or abstract
Authors: Maurel, J, Taberner, M, Rodriguez-Salas, N, Aparicio, J, Virgili, A, Capdevila, J, Munoz Boza, F, Alvarez, R, Bosch, C, Camara, J et al.
DOI: 10.1093/annonc/mdz155.190

Randomized phase II clinical trial to evaluate the efficacy of second-line FOLFIRI-panitumumab in patients with RAS wild-type metastatic colorectal cancer who have received FOLFOX-panitumumab in first-line (BEYOND).

PMID: 32085197
Journal: ANNALS OF ONCOLOGY
Year: 2019
Reference: Ann Oncol. 2019 Jul;30 Suppl 4:iv52. doi: 10.1093/annonc/mdz155.190. Epub 2019 Dec 4.
Impact factor:
Publication type: Letter or abstract
Authors: Alvarez, R; Aparicio, J; Bosch, C; Camara, J; Capdevila, J; Fernandez-Martos, C; Fernandez-Plana, J; Gallego, J; Gallego, R; Hernandez-Yague, X et al.
DOI: 10.1093/annonc/mdz155.190

Randomized Phase II Trial of Seribantumab in Combination with Erlotinib in Patients with EGFR Wild-Type Non-Small Cell Lung Cancer.

PMID: 30975923
Journal: ONCOLOGIST
Year: 2019
Reference: Oncologist. 2019 Aug;24(8):1095-1102. doi: 10.1634/theoncologist.2018-0695. Epub 2019 Apr 11.
Impact factor: 5.252
Publication type: Paper in international publication
Authors: Lopez-Chavez, Ariel, Doebele, Robert C, Modiano, Manuel R, Jackman, David Michael, Baggstrom, Maria Quintos, Atmaca, Akin, Felip, Enriqueta, Provencio, Mariano, Cobo, Manuel, Adiwijaya, Bambang et al.
DOI: 10.1634/theoncologist.2018-0695

Randomized Phase II Trial of Seribantumab in Combination with Erlotinib in Patients with EGFR Wild-Type Non-Small Cell Lung Cancer.

PMID: 30975923
Journal: ONCOLOGIST
Year: 2019
Reference: Oncologist. 2019 Aug;24(8):1095-1102. doi: 10.1634/theoncologist.2018-0695. Epub 2019 Apr 11.
Impact factor:
Publication type: Paper in international publication
Authors: Adiwijaya, Bambang; Andreas, Karen; Atmaca, Akin; Baggstrom, Maria Quintos; Cho, Byoung Chul; Cobo, Manuel; Doebele, Robert C; Felip, Enriqueta; Gray, Jhanelle Elaine; Harb, Wael A et al.
DOI: 10.1634/theoncologist.2018-0695

Randomized Phase III Trial of Ibrutinib and Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone in Non-Germinal Center B-Cell Diffuse Large B-Cell Lymphoma.

PMID: 30901302
Journal: JOURNAL OF CLINICAL ONCOLOGY
Year: 2019
Reference: J Clin Oncol. 2019 May 20;37(15):1285-1295. doi: 10.1200/JCO.18.02403. Epub 2019 Mar 22.
Impact factor: 28.245
Publication type: Paper in international publication
Authors: Turgut, Mehmet, Jurczak, Wojciech, Cheung, Matthew C, Gurion, Ronit, Yeh, Su-Peng, Lopez-Hernandez, Andres, Duhrsen, Ulrich, Thieblemont, Catherine, Chiattone, Carlos Sergio, Balasubramanian, Sriram et al.
DOI: 10.1200/JCO.18.02403

Publications

Publications searcher

Quality assurance in specialized headache units in Spain: an observational prospective study.

Quantification of urinary derivatives of Phenylbutyric and Benzoic acids by LC-MS/MS as treatment compliance biomarkers in Urea Cycle disorders.

Quantification of urinary derivatives of Phenylbutyric and Benzoic acids by LC-MS/MS as treatment compliance biomarkers in Urea Cycle disorders.

Radiation Exposure from Fluoroscopy during Hip Arthroscopy.

Radiation Exposure from Fluoroscopy during Hip Arthroscopy.

Radical Hysterectomy: Efficacy and Safety in the Dawn of Minimally Invasive Techniques.

Radical Hysterectomy: Efficacy and Safety in the Dawn of Minimally Invasive Techniques.

Radiotherapy practice for paediatric brain tumours across Europe and quality assurance initiatives: Current situation, international survey and future perspectives.

Radiotherapy practice for paediatric brain tumours across Europe and quality assurance initiatives: Current situation, international survey and future perspectives.

Radium-223 in asymptomatic patients with castration-resistant prostate cancer and bone metastases treated in an international early access program.

Radium-223 in asymptomatic patients with castration-resistant prostate cancer and bone metastases treated in an international early access program.

Ramucirumab plus pembrolizumab in patients with previously treated advanced non-small-cell lung cancer, gastro-oesophageal cancer, or urothelial carcinomas (JVDF): a multicohort, non-randomised, open-label, phase 1a/b trial.

Ramucirumab plus pembrolizumab in patients with previously treated advanced non-small-cell lung cancer, gastro-oesophageal cancer, or urothelial carcinomas (JVDF): a multicohort, non-randomised, open-label, phase 1a/b trial.

Ramucirumab with cisplatin and fluoropyrimidine as first-line therapy in patients with metastatic gastric or junctional adenocarcinoma (RAINFALL): a double-blind, randomised, placebo-controlled, phase 3 trial.

Ramucirumab with cisplatin and fluoropyrimidine as first-line therapy in patients with metastatic gastric or junctional adenocarcinoma (RAINFALL): a double-blind, randomised, placebo-controlled, phase 3 trial.

Randomised phase 2 study of pembrolizumab plus CC-486 versus pembrolizumab plus placebo in patients with previously treated advanced non-small cell lung cancer.

Randomised phase 2 study of pembrolizumab plus CC-486 versus pembrolizumab plus placebo in patients with previously treated advanced non-small cell lung cancer.

Randomized, Double-blind, Placebo-controlled, Multicenter Study of Siltuximab in High-risk Smoldering Multiple Myeloma.

Randomized, Double-blind, Placebo-controlled, Multicenter Study of Siltuximab in High-risk Smoldering Multiple Myeloma.

Randomized phase II clinical trial to evaluate the efficacy of second-line FOLFIRI-panitumumab in patients with RAS wild-type metastatic colorectal cancer who have received FOLFOX-panitumumab in first-line (BEYOND).

Randomized phase II clinical trial to evaluate the efficacy of second-line FOLFIRI-panitumumab in patients with RAS wild-type metastatic colorectal cancer who have received FOLFOX-panitumumab in first-line (BEYOND).

Randomized Phase II Trial of Seribantumab in Combination with Erlotinib in Patients with EGFR Wild-Type Non-Small Cell Lung Cancer.

Randomized Phase II Trial of Seribantumab in Combination with Erlotinib in Patients with EGFR Wild-Type Non-Small Cell Lung Cancer.

Randomized Phase III Trial of Ibrutinib and Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone in Non-Germinal Center B-Cell Diffuse Large B-Cell Lymphoma.

Patronage:

Collaborating:

Accreditations: